Table 1.
Clinical characteristics of patients receiving palbociclib for mBC at Taipei Veterans General Hospital.
| Characteristics | Number | Percentage | |
|---|---|---|---|
| Patients, n | 105 | ||
| Median age, y | 56.9 | ||
| Female, % | 100 | ||
| Premenopausal | 12 | 11.43% | |
| Median BMI | 23.72 | ||
| Median height (cm) | 155.8 | ||
| Median weight (kg) | 57.5 | ||
| Lung metastasis | 70 | 66.7% | |
| Liver metastasis | 50 | 47.6% | |
| Median PFS | 503 (17.9 months) | ||
| Median OS | 968 (32.27 months) | ||
| Death events | 53 | 50.4% | |
| 1L | 57 | 54.28% | |
| 2L | 15 | 14.29% | |
| ≥3L | 33 | 31.43% | |
| Response | |||
| CR | 0 | ||
| PR | 39 | 37.8% | |
| SD | 54 | 52.4% | |
| PD | 10 | 9.7% | |
| ORR | 39/103 | 37.8% | |
| In first-line patients | |||
| Median PFS | 612 (20.4 months) | ||
| Median OS | Not reached | ||
| Progression/death events | 36 | 63.2% | |
| Death events | 19 | 33.3% | |
| PFS of second-line treatment | 176 (5.87 months) | ||
| PFS2 | 883 (29.4 months) | ||
| ORR | 47.4% | ||
| In second-line patients | |||
| Median follow-up time | 870 days (29 months) | ||
| Median PFS | 318 days (10.6 months) | ||
| Median OS | Not reached | ||
| Progression/death events | 13 | 86.67% | |
| Death events | 5 | 33.3% | |
| PFS2 | 562 (17.7 months) | ||
| ORR | 33.3% | ||
| In third-line patients | |||
| Median PFS | 181 days (6.0 months) | ||
| Median OS | 710 days (23.7 months) | ||
| Progression/death events | 26 | 76.5%% | |
| Death events | 23 | 67.6% | |
| PFS2 | 413 (13.8 months) | ||
| ORR | 21.2% | CR 0, PR 7, SD 18, PD 8 | |
| Dose reduction | 30 | 28.6% | |
| Patients reached neutrophil nadir <56 days | 56 | 55.4% | |
| Entire cohort | Early neutropenia | Delayed neutropenia | P-value |
| Patient number | 56 | 55 | |
| Median age | 60 | 57.3 | .718 |
| Dose reductions | 17 | 13 | |
| % of dose reductions | 30.3% | 28.9% | 1.00 |
| Liver metastases (%) | 64.3 | 60 | .56 |
| Lung metastases (%) | 44.6 | 41.8 | 1.00 |
| Bone metastases (%) | 73.2 | 70.1 | .49 |